The sodium-glucose cotransporter 2 inhibitor (SGLT2i) is one of the cornerstones of guideline-directed medical therapy for heart failure and has been shown to reduce the risk of mortality and heart failure hospitalization, and improve functional status and quality of life in patients with heart failure.1 The gene discussed is SLC5A2; the disease is heart failure.